OBJECTIVES

To perform a budget impact analysis (BIA) of introducing Olaparib as maintenance therapy in BRCA-mutated (BRCAm) women with platinum sensitive recurrent ovarian cancer (PSROC), from the perspective of the Social Health Insurance (EsSalud).

METHODS

A global BIA model was used to analyse over a 5-year time horizon the change in the EsSalud´s expenditure following the adoption of Olaparib as maintenance therapy in BRCAm patients with PSROC. The financial impact for each year was estimated by comparing the cost of changing the current standard of care (“watch and wait”) with the adoption of Olaparib for the whole targeted population (considering an 100% uptake of Olaparib annually). National epidemiological data was used to determine the patient population. Clinical efficacy and safety outcomes were obtained from the clinical study report for Study 19 (NCT00753545). Healthcare resource use was determined through local data. Relevant costs to EsSalud related with patient follow-up, serious adverse events management, and subsequent chemotherapy were obtained from the National Tariff (RJ-599-2014) and the Peruvian Ministry of Health website. BRCAm testing costs were not included in the analysis. The analysis did not considered costs associated with induction therapy, subsequent therapy and end-of-life care (assuming these costs would have a minimal budget impact).

RESULTS

The annual incremental costs resulting from switching “watch and wait” to Olaparib were $983,740; $1,000,167; $1,013,789; $1,029,198 and $ 1,044,842 (years 1 to 5).

CONCLUSIONS

The analysis suggests that the clinical benefit of replacing “watch and wait” strategy with Olaparib in a group of patients without any current therapeutic option available (BRCAm women with PSROC), provides predictable costs for supporting the planning and decision-making process of payers in Peru.